Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
HEM | TSXV | CAD | Delayed | |
HEM | CBOE Canada | CAD | Real-time |
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.
Name | Age | Since | Title |
---|---|---|---|
Hari L. Kumar | - | 2017 | Member of Scientific Advisory Board |
Alan B. Lumsden | - | - | Member of Scientific Advisory Board |
York N. Hsiang | - | 2020 | Member of Scientific Advisory Board |
Peter Alan Lacey | 68 | 2020 | Independent Chairman |
Thomas A. Smeenk | 62 | 2019 | Co-Founder, President, CEO & Director |
Ernst von Schwarz | - | 2022 | Member of Scientific Advisory Board |
Norman C. W. Wong | - | 2017 | Member of Scientific Advisory Board |
Loran Swanberg | - | 2020 | Independent Director |
Sheila Copps | - | 2020 | Member of Board of Advisors |
Ronnie Allen Hershman | - | 2020 | Independent Director |
Johannes Grillari | - | 2022 | Scientific Advisory Board |
David H. Tsubouchi | 72 | 2020 | Member of Board of Advisors |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review